Episodes
-
In this episode of Diagnosing Dx, David Filby is joined by Talia Cohen Solal, CEO at NeuroKaire.
Talia is a neuroscientist by training who spent more than a decade in academia, including time at Oxford, UCL, and Columbia, before moving into the startup world to get closer to real patient impact. In this conversation, we explore why precision medicine has transformed fields like oncology but still has so far to go in psychiatry, and how NeuroKaire is trying to change that.
We discuss the limits of current antidepressant prescribing and how NeuroKaire is using patient-derived neurons to predict which treatments are most likely to work for each individual.
This is a practical conversation about precision psychiatry, commercialization, clinical evidence, and what it takes to bring better mental health diagnostics into real patient care.
Key takeaways:
🔹 Why psychiatry still lacks the precision medicine approach seen in other fields
🔹 How NeuroKaire is using patient-derived neurons to guide antidepressant treatment
🔹 Why clinical trials and guideline change are essential for real adoption
🔹 How the company is balancing commercial growth with platform expansion and pharma partnerships
🔹 What the future could look like for diagnostics in depression, anxiety, ADHD, and beyondGuest: Talia Cohen Solal
CEO at NeuroKaireLinkedIn: https://www.linkedin.com/in/talia-cohen-solal-5b49a78/
Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/Chapters:
00:00 Introduction to Talia Cohen Solal and her background
08:23 Transitioning from academia to startups
09:52 The vision behind NeuroKaire and precision psychiatry
12:38 Clinical trials and validation of NeuroKaire’s technology
14:37 Commercialization, distribution, and reimbursement
16:46 Education and awareness in the medical community
19:44 Future growth, market potential, and new indications
26:47 Outlook on diagnostics and the future of neurodiagnostics🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
-
In this episode of Diagnosing Dx, David Filby is joined by Bharat Tewarie, MD, MBA, CEO at Helio Genomics.
Bharat has led Helio Genomics since July 2025, bringing decades of global healthcare leadership across pharma, biotech, diagnostics, and digital health. In this conversation, we explore why liver cancer surveillance still relies too heavily on outdated imaging, why so many high-risk patients fall through the cracks, and how Helio Genomics is trying to change that with HelioLiver, its blood-based test designed to improve early detection.
We discuss the limitations of ultrasound in liver cancer screening, the promise of AI-powered multiomics, and why early detection only matters if patients can actually access it. Bharat also shares how his clinical and commercial background shapes Helio’s strategy, from workflow design and physician adoption to partnerships, awareness, and the infrastructure needed to move from scientific validation to real clinical impact.
This is a practical conversation about liver cancer, access, commercialization, and what it takes to turn better diagnostics into better outcomes.
Key takeaways:
🔹 Why liver cancer surveillance still leaves too many high-risk patients undetected
🔹 How AI-powered multiomics and HelioLiver could improve early liver cancer detection
🔹 Why access and workflow matter just as much as scientific performance
🔹 How partnerships can accelerate commercialization and patient reach
🔹 What Helio Genomics is building beyond HelioLiver as it expands its platform
Guest: Bharat Tewarie, MD, MBA
CEO at Helio Genomics
LinkedIn: https://www.linkedin.com/in/bharattewarie/
Host: David Filby
Founder and CEO of Elevra Consulting
LinkedIn: https://www.linkedin.com/in/davidfilby/
Chapters:
00:00 Introduction to Bharat Tewarie and Helio Genomics
01:42 Bharat’s journey from medicine to business
06:25 The evolution of diagnostics, omics, and AI
10:36 Helio Genomics’ mission and differentiators
12:03 Unmet needs in liver cancer surveillance
14:01 Awareness, access, and clinical workflow challenges
19:10 The role of partnerships in commercialization
26:27 Growth strategy and the future of diagnostics🔔 Subscribe to Diagnosing Dx for weekly conversations with leaders shaping the future of diagnostics and omics.
-
Missing episodes?
